Table 1.
Neuropsychological, clinical, and demographic characteristics of the groups
| Cohort | Working memory performance
|
Full scale IQ | Age, yr | Age at onset of illness, yr | Duration of illness, yr | Anti-psychotic medication, mg/day | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number of correct responses* | Reaction time, s | PANSS subscale ratings
|
||||||||
| Positive | Negative | General psychopathology | ||||||||
| T1 | 9.1 (2.23) | 0.78 (0.21) | 108.2 (11.96) | 37.2 (8.1) | 8.4 (1.6) | 10.7 (3.5) | 20.2 (4.5) | 24.3 (6.5) | 12.9 (6.6) | 194.5 (168.8) |
| T2 | 9.9 (2.18) | 0.82 (0.19) | 10.0 (3.1) | 10.8 (4.1) | 21.8 (4.8) | 216.5 (164.2) | ||||
| R1 | 10.6 (0.53) | 0.67 (0.15) | 100.9 (14.9) | 37.6 (13.4) | 13.5 (3.9) | 15.3 (6.0) | 28.1 (7.5) | 25 (6.8) | 12.6 (10.1) | 282.9 (161.3) |
| R2 | 10.1 (1.52) | 0.6 (0.15) | 12.1 (4.4) | 12.3 (4.9) | 25.6 (7.3) | 4.6 (1.7) | ||||
| C | 10.9 (0.32) | 0.5 (0.11) | 110.9 (5.7) | 38.9 (9.7) | — | — | — | — | — | — |
T1, typically treated patient cohort at baseline; T2, typically treated patient cohort at 6 weeks; R1, risperidone-treated cohort at baseline; R2, risperidone-treated cohort at 6 weeks; C, comparison subjects. PANSS, Positive and Negative Syndrome Scale for Schizophrenia (27). Dose of antipsychotic medication is given as chlorpromazine equivalents, with the exception of R2, where the dose is of risperidone. Standard deviations are given in parentheses.
*
Maximum = 11.